Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Through a prospective, single-center, single-arm, phase Ib/II study, we aim to explore the
safety and feasibility of a new treatment mode for upper esophageal cancer, which is that
pembrolizumab combined with chemoradiotherapy as neoadjuvant therapy and then followed by
radical surgery.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences